5. Clinical laboratory testing including but not li mited to: CBC with differential and platelet count, total serum bilirubin, alkaline phosphatase, AST (SGOT), ALT (SGPT), serum creatinine, serum electrolytes, serum calcium and serum albumin . Urine β- HCG (for women of child bearing potential). NOTE: If clinical screening labs (CBC and Chemistry) were performed within 72 hours prior to the subject’s first immunotherapy, these labs are not required to be redrawn prior to the subject’s first immunotherapy. 6. Whole blood and serum for baseline immunologic assays. The following study evaluations will be performed on the same day post- immunotherapy: 1. Injection site reaction assessment within 30 -45 minutes after EP . 2. Review of adverse events. 3. Data should be downloaded from the EP device 4. Distribute participant reminder card to be reviewed at the next visit. 6.2.3 2 Week Follow Up Post Last Dose of Immunotherapy (± 3 days) 1. Medical/Clinical assessment including concurrent medications/treatments.